Federico Paolieri

TL;DR: The Meet-URO score allowed for the accurate stratification of pretreated mRCC patients receiving nivolumab and is easily applicable for clinical practice at no additional cost.

TL;DR: To investigate if full‐length androgen receptors (AR‐FL) is associated with resistance to androgen receptor (AR)‐directed therapy independently and/or combined with AR splice variant 7 ( AR‐V7).

TL;DR: It is found that the Multi-Prognostic Index score is an effective tool for the stratification of older patients with cancer eligible for immunotherapy with checkpoint inhibitors and further studies are required to achieve conclusive remarks on MPI usefulness in different underlying tumor types.

TL;DR: An association between CYP17A1 c.-362T>C polymorphism and poorer clinical outcome with abiraterone for mCRPC patients is suggested, however, further validations on larger cohort of patients are needed to confirm its role as a predictive biomarker for abIRaterone resistance.

TL;DR: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0, according to retrospective analysis of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazop anib in patients with metastatic renal cell carcinoma.